Correct application of variant classification guidelines in germline
RUNX1
mutated disorders to assist clinical diagnosis
Leuk Lymphoma
.
2020 Jan;61(1):246-247.
doi: 10.1080/10428194.2019.1680842.
Epub 2019 Oct 24.
Authors
Anna L Brown
1
2
3
,
Christopher Hahn
1
2
3
,
Devendra Hiwase
3
4
5
,
Lucy A Godley
6
7
,
Hamish S Scott
1
2
3
Affiliations
1
Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia.
2
Centre for Cancer Biology, SA Pathology & University of South Australia, Adelaide, Australia.
3
School of Medicine, University of Adelaide, Adelaide, Australia.
4
Department of Haematology, Royal Adelaide Hospital, Central Adelaide Local Health Network Adelaide, Adelaide, Australia.
5
Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, Australia.
6
Department of Medicine, Center for Clinical Cancer Genetics, The University of Chicago, Chicago, IL, USA.
7
Section of Hematology/Oncology, The University of Chicago Comprehensive Cancer Center, Chicago, IL, USA.
PMID:
31647332
DOI:
10.1080/10428194.2019.1680842
No abstract available
Publication types
Letter
Comment
MeSH terms
Core Binding Factor Alpha 2 Subunit
Genomics
Germ Cells
Humans
Leukemia, Myeloid, Acute*
Myelodysplastic Syndromes*
Substances
Core Binding Factor Alpha 2 Subunit
RUNX1 protein, human